BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 36354730)

  • 1. Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
    Potre C; Borsi E; Potre O; Samfireag M; Costachescu D; Cerbu B; Bratosin F; Secosan C; Negrean RA
    Curr Oncol; 2022 Nov; 29(11):8501-8512. PubMed ID: 36354730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
    Moreau P; Hebraud B; Facon T; Leleu X; Hulin C; Hashim M; Hu Y; Caillot D; Benboubker L; Zweegman S; Merz M; Weisel K; Salwender H; Mai EK; Goldschmidt H; Bertsch U; Vanquickelberghe V; Kampfenkel T; Boer C; Krotneva S; Proskorovsky I; He J; Lam A; Lee C; Cote S; Sonneveld P
    Immunotherapy; 2021 Feb; 13(2):143-154. PubMed ID: 33228440
    [No Abstract]   [Full Text] [Related]  

  • 5. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
    Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
    Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
    Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
    Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
    Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
    Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
    Roussel M; Moreau P; Hebraud B; Laribi K; Jaccard A; Dib M; Slama B; Dorvaux V; Royer B; Frenzel L; Zweegman S; Klein SK; Broijl A; Jie KS; Wang J; Vanquickelberghe V; de Boer C; Kampfenkel T; Gries KS; Fastenau J; Sonneveld P
    Lancet Haematol; 2020 Dec; 7(12):e874-e883. PubMed ID: 33242444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
    Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
    Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
    Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
    Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India.
    Dixit J; Malhotra P; Mehra N; Mathew A; Kumar L; Singh A; Gupta N; Krishnamurthy MN; Roy PS; Kataki AC; Gupta S; Prinja S
    Appl Health Econ Health Policy; 2024 Jul; 22(4):569-582. PubMed ID: 38448720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma.
    Lee YJ; Moon JH; Sohn SK; Kim SJ; Jung SH; Lee JJ; Jo JC; Shin HJ; Lee WS; Lee JH; Bae SH; Kim MK; Lee HS; Kim K; Min CK;
    Bone Marrow Transplant; 2019 Dec; 54(12):2051-2059. PubMed ID: 31358918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
    Vigolo S; Zuckermann J; Bittencourt RI; Silla L; Pilger DA
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):135-142. PubMed ID: 28636891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
    Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P
    Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
    Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
    Jackson GH; Pawlyn C; Cairns DA; de Tute RM; Hockaday A; Collett C; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Rocci A; Snowden JA; Jenner MW; Cook G; Russell NH; Drayson MT; Gregory WM; Kaiser MF; Owen RG; Davies FE; Morgan GJ;
    PLoS Med; 2021 Jan; 18(1):e1003454. PubMed ID: 33428632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
    Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Allotey D; Shafeek S; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Clinical Studies Group UNHO
    Haematologica; 2021 Jul; 106(7):1957-1967. PubMed ID: 32499244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
    Togano T; Andoh S; Komuro M; Mitsui Y; Itoi S; Hirai R; Nakamura M; Tanimura A; Sekine R; Takeshita M; Miwa A; Hagiwara S
    Intern Med; 2022 Nov; 61(22):3329-3334. PubMed ID: 35466165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.